Thursday, February 20, 2020
Home Tags Fbio

Tag: fbio

biotech stock review ATXI
Biotech News

Avenue Therapeutics (ATXI) Announces New Drug Application for IV Tramadol Accepted...

Editor / Curator -
Biotech News

Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.

Editor / Curator -
Immunomedics, Biotech Stock Review
All News

Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in...

Editor / Curator -
All News

Citius Pharma (CTXR), Fortress Biotech (FBIO) and True Nature (TNTY) Significantly...

Editor / Curator -
Biotech News

Frontier Bio (FBIO) Bolstering it’s Warchest.

Editor / Curator -
Lindsay Rosenwald, Biotech Stock Review
Biotech News

Newsworthy: Fortress Bio (FBIO) $1.73, Gets $20 Price Target!

Editor / Curator -
Biotech News

Cougar Biotechnology. A $500,000 Investment Acquired for $1 Billion.

Editor / Curator -
Mustang Bio
Biotech News

Mustang Bio (MBIO) Investor Presentation

Editor / Curator -
Dr. Lindsay Rosenwald
Biotech News

Dr Lindsay Rosenwald, Biography.

Editor / Curator -

Latest article

biotech stock review ATXI

Avenue Therapeutics (ATXI) Announces New Drug Application for IV Tramadol Accepted for Review by...

Biotech News Editor / Curator -
IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.

Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.

Biotech News Editor / Curator -
Fortress Bio (FBIO) Inches Closer to $3.00 on Major News. Citius Pharma (CTXR) Inches Closer to the Next Phase...

Video: How Superbugs Get Started.

All News Editor / Curator -
A World Health Organization (WHO) report released April 2014 stated, "this serious threat is no longer a prediction for the future, it is happening...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.